Bleeding related to disturbed fibrinolysis

British Journal of Haematology

Volumn 175, Issue 1, 2016, Pages 12-23

  Kolev, Krasimir ^a   Longstaff, Colin ^b  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

Author keywords

acute promyelocytic leukaemia; antiplasmin; bleeding disorders; fibrinolysis; plasminogen activator inhibitor type 1

Indexed keywords

ALPHA 2 ANTIPLASMIN; ALTEPLASE; AMINOCAPROIC ACID; APROTININ; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; TRANEXAMIC ACID;

ALCOHOL LIVER DISEASE; BLOOD CLOTTING FACTOR 11 DEFICIENCY; BLOOD CLOTTING FACTOR 13 DEFICIENCY; DISEASE PREDISPOSITION; DISEASE SEVERITY; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME INHIBITION; FIBRINOLYSIS; HEMOPHILIA A; HEMOPHILIA B; HETEROZYGOTE; HUMAN; IN VIVO STUDY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; RARA GENE; REVIEW; SERPINE1 GENE; STOP CODON; TREND STUDY;

EID: 84988515809     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.14255     Document Type: Review

References (101)

1. Ajzner, E., Schlammadinger, A., Kerenyi, A., Bereczky, Z., Katona, E., Haramura, G., Boda, Z. & Muszbek, L. (2009) Severe bleeding complications caused by an autoantibody against the B subunit of plasma factor XIII: a novel form of acquired factor XIII deficiency. Blood, 113, 723–725.
2. Ammollo, C.T., Semeraro, F., Xu, J., Esmon, N.L. & Esmon, C.T. (2011) Extracellular histones increase plasma thrombin generation by impairing thrombomodulin-dependent protein C activation. Journal of Thrombosis and Haemostasis, 9, 1795–1803.
3. Antovic, A., Mikovic, D., Elezovic, I., Zabczyk, M., Hutenby, K. & Antovic, J.P. (2014) Improvement of fibrin clot structure after factor VIII injection in haemophilia A patients treated on demand. Thrombosis and Haemostasis, 111, 656–661.
4. Anwar, R. & Miloszewski, K.J. (1999) Factor XIII deficiency. British Journal of Haematology, 107, 468–484.
5. Aoki, N., Saito, H., Kamiya, T., Koie, K., Sakata, Y. & Kobakura, M. (1979) Congenital deficiency of alpha 2-plasmin inhibitor associated with severe hemorrhagic tendency. J Clin Invest, 63, 877–884.
6. Blavignac, J., Bunimov, N., Rivard, G.E. & Hayward, C.P. (2011) Quebec platelet disorder: update on pathogenesis, diagnosis, and treatment. Seminars in Thrombosis and Hemostasis, 37, 713–720.
7. de Bono, D.P. & More, R.S. (1993) Prevention and management of bleeding complications after thrombolysis. International Journal of Cardiology, 38, 1–6.
8. Booth, N.A., Anderson, J.A. & Bennett, B. (1984) Plasminogen activators in alcoholic cirrhosis: demonstration of increased tissue type and urokinase type activator. Journal of Clinical Pathology, 37, 772–777.
9. Bridge, K.I., Philippou, H. & Ariens, R. (2014) Clot properties and cardiovascular disease. Thrombosis and Haemostasis, 112, 901–908.
10. Brohi, K., Cohen, M.J., Ganter, M.T., Schultz, M.J., Levi, M., Mackersie, R.C. & Pittet, J.F. (2008) Acute coagulopathy of trauma: hypoperfusion induces systemic anticoagulation and hyperfibrinolysis. Journal of Trauma, 64, 1211–1217; discussion 1217.
11. Broze, G.J. & Higuchi, D.A. (1996) Coagulation-dependent inhibition of fibrinolysis: role of carboxypeptidase-U and the premature lysis of clots from hemophilic plasma. Blood, 88, 3815–3823.
12. Brummel-Ziedins, K.E., Branda, R.F., Butenas, S. & Mann, K.G. (2009) Discordant fibrin formation in hemophilia. Journal of Thrombosis and Haemostasis, 7, 825–832.
13. Casini, A., Neerman-Arbez, M., Ariens, R.A. & de Moerloose, P. (2015) Dysfibrinogenemia: from molecular anomalies to clinical manifestations and management. Journal of Thrombosis and Haemostasis, 13, 909–919.
14. Cawthern, K.M., van‘t Veer, C., Lock, J.B., DiLorenzo, M.E., Branda, R.F. & Mann, K.G. (1998) Blood coagulation in hemophilia A and hemophilia C. Blood, 91, 4581–4592.
15. Christensen, U. (1978) Allosteric effects of some antifibrinolytic amino acids on the catalytic activity of human plasmin. Biochimica et Biophysica Acta, 526, 194–201.
16. Colucci, M., Binetti, B.M., Branca, M.G., Clerici, C., Morelli, A., Semeraro, N. & Gresele, P. (2003) Deficiency of thrombin activatable fibrinolysis inhibitor in cirrhosis is associated with increased plasma fibrinolysis. Hepatology, 38, 230–237.
17. Colucci, G., Alberio, L., Jahns, M., Keller, P., Steiner, S., Rusges-Wolter, I. & Lammle, B. (2009) Effective therapy with tranexamic acid in a case of chronic disseminated intravascular coagulation with acquired alpha2-antiplasmin deficiency associated with AL amyloidosis. Thrombosis and Haemostasis, 102, 1285–1287.
18. Das, R., Burke, T. & Plow, E.F. (2007) Histone H2B as a functionally important plasminogen receptor on macrophages. Blood, 110, 3763–3772.
19. Dombret, H., Scrobohaci, M.L., Ghorra, P., Zini, J.M., Daniel, M.T., Castaigne, S. & Degos, L. (1993) Coagulation disorders associated with acute promyelocytic leukemia: corrective effect of all-trans retinoic acid treatment. Leukemia, 7, 2–9.
20. Edmunds, L.H. Jr (2010) Managing fibrinolysis without aprotinin. Annals of Thoracic Surgery, 89, 324–331.
21. Fay, W.P., Shapiro, A.D., Shih, J.L., Schleef, R.R. & Ginsburg, D. (1992) Brief report: complete deficiency of plasminogen-activator inhibitor type 1 due to a frame-shift mutation. New England Journal of Medicine, 327, 1729–1733.
22. Fay, W.P., Parker, A.C., Condrey, L.R. & Shapiro, A.D. (1997) Human plasminogen activator inhibitor-1 (PAI-1) deficiency: characterization of a large kindred with a null mutation in the PAI-1 gene. Blood, 90, 204–208.
23. Fiechtner, B.K., Nuttall, G.A., Johnson, M.E., Dong, Y., Sujirattanawimol, N., Oliver, W.C. Jr, Sarpal, R.S., Oyen, L.J. & Ereth, M.H. (2001) Plasma tranexamic acid concentrations during cardiopulmonary bypass. Anesthesia and Analgesia, 92, 1131–1136.
24. Foley, J.H. & Nesheim, M.E. (2009) Soluble thrombomodulin partially corrects the premature lysis defect in FVIII-deficient plasma by stimulating the activation of thrombin activatable fibrinolysis inhibitor. Journal of Thrombosis and Haemostasis, 7, 453–459.
25. Forbes, C.D., Barr, R.D., Reid, G., Thomson, C., Prentice, C.R., McNicol, G.P. & Douglas, A.S. (1972) Tranexamic acid in control of haemorrhage after dental extraction in haemophilia and Christmas disease. British Medical Journal, 2, 311–313.
26. Fraser, S.R., Booth, N.A. & Mutch, N.J. (2011) The antifibrinolytic function of factor XIII is exclusively expressed through alpha(2)-antiplasmin cross-linking. Blood, 117, 6371–6374.
27. Fuchs, T.A., Bhandari, A.A. & Wagner, D.D. (2011) Histones induce rapid and profound thrombocytopenia in mice. Blood, 118, 3708–3714.
28. van Geffen, M. & van Heerde, W.L. (2012) Global haemostasis assays, from bench to bedside. Thrombosis Research, 129, 681–687.
29. Goodpasture, E.W. (1914) Fibrinolysis and chronic hepatic insufficiency. Bulletin of the Johns Hopkins Hospital, 25, 330–336.
30. Grignani, F., Ferrucci, P.F., Testa, U., Talamo, G., Fagioli, M., Alcalay, M., Mencarelli, A., Grignani, F., Peschle, C., Nicoletti, I. & Pelicci, P.G. (1993) The acute promyelocytic leukemia-specific PML-RAR alpha fusion protein inhibits differentiation and promotes survival of myeloid precursor cells. Cell, 74, 423–431.
31. Grunewald, M., Siegemund, A., Grunewald, A., Konegan, A., Koksch, M. & Griesshammer, M. (2002) Paradoxical hyperfibrinolysis is associated with a more intensely haemorrhagic phenotype in severe congenital haemophilia. Haemophilia, 8, 768–775.
32. Gunawan, B. & Runyon, B. (2006) The efficacy and safety of epsilon-aminocaproic acid treatment in patients with cirrhosis and hyperfibrinolysis. Alimentary Pharmacology & Therapeutics, 23, 115–120.
33. He, S., Zhu, K., Skeppholm, M., Vedin, J., Svensson, J., Egberg, N., Blombäck, M. & Wallen, H. (2007) A global assay of haemostasis which uses recombinant tissue factor and tissue-type plasminogen activator to measure the rate of fibrin formation and fibrin degradation in plasma. Thrombosis and Haemostasis, 98, 871–882.
34. Henry, D.A., Carless, P.A., Moxey, A.J., O'Connell, D., Stokes, B.J., Fergusson, D.A. & Ker, K. (2011) Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database Systematic Review, Art. No. CD001886.
35. Hethershaw, E.L., Cilia La Corte, A.L., Duval, C., Ali, M., Grant, P.J., Ariëns, R.A.S. & Philippou, H. (2014) The effect of blood coagulation factor XIII on fibrin clot structure and fibrinolysis. Journal of Thrombosis and Haemostasis: JTH, 12, 197–205.
36. Hijazi, N., Abu Fanne, R., Abramovitch, R., Yarovoi, S., Higazi, M., Abdeen, S., Basheer, M., Maraga, E., Cines, D.B. & Higazi, A.A. (2015) Endogenous plasminogen activators mediate progressive intracerebral hemorrhage after traumatic brain injury in mice. Blood, 125, 2558–2567.
37. Horrevoets, A.J.G., Pannekoek, H. & Nesheim, M.E. (1997) A steady-state template model that describes the kinetics of fibrin- stimulated. Journal of Biological Chemistry, 272, 2183–2191.
38. Hyman, D.M., Soff, G.A. & Kampel, L.J. (2011) Disseminated intravascular coagulation with excessive fibrinolysis in prostate cancer: a case series and review of the literature. Oncology, 81, 119–125.
39. Janning, M., Holstein, K., Spath, B., Schnabel, C., Bannas, P., Bokemeyer, C. & Langer, F. (2013) Relevant bleeding diathesis due to acquired factor XIII deficiency. Hamostaseologie, 33, S50–S54.
40. Kashuk, J.L., Moore, E.E., Sawyer, M., Wohlauer, M., Pezold, M., Barnett, C., Biffl, W.L., Burlew, C.C., Johnson, J.L. & Sauaia, A. (2010) Primary fibrinolysis is integral in the pathogenesis of the acute coagulopathy of trauma. Annals of Surgery, 252, 434–442; discussion 443-434.
41. Kluft, C., Vellenga, E., Brommer, E.J. & Wijngaards, G. (1982) A familial hemorrhagic diathesis in a Dutch family: an inherited deficiency of alpha 2-antiplasmin. Blood, 59, 1169–1180.
42. Kovacs, A., Szabo, L., Longstaff, C., Tenekedjiev, K., Machovich, R. & Kolev, K. (2014) Ambivalent roles of carboxypeptidase B in the lytic susceptibility of fibrin. Thrombosis Research, 133, 80–87.
43. Law, R.H., Abu-Ssaydeh, D. & Whisstock, J.C. (2013) New insights into the structure and function of the plasminogen/plasmin system. Current Opinion in Structural Biology, 23, 836–841.
44. Lee, C.D. & Mann, K.G. (1989) Activation/inactivation of human factor V by plasmin. Blood, 73, 185–190.
45. Lisman, T. (2012) Fibrinolysis in liver disease. Journal of Thrombosis and Haemostasis, 10, e25.
46. Lisman, T., Leebeek, F.W., Mosnier, L.O., Bouma, B.N., Meijers, J.C., Janssen, H.L., Nieuwenhuis, H.K. & De Groot, P.G. (2001) Thrombin-activatable fibrinolysis inhibitor deficiency in cirrhosis is not associated with increased plasma fibrinolysis. Gastroenterology, 121, 131–139.
47. Liu, Y., Wang, Z., Jiang, M., Dai, L., Zhang, W., Wu, D. & Ruan, C. (2011) The expression of annexin II and its role in the fibrinolytic activity in acute promyelocytic leukemia. Leukemia Research, 35, 879–884.
48. Longstaff, C. (1994) Studies on the mechanisms of action of aprotinin and tranexamic acid as plasmin inhibitors and antifibrinolytic agents. Blood Coagulation & Fibrinolysis, 5, 537–542.
49. Longstaff, C. & Gaffney, P.J. (1991) Serpin-serine protease binding kinetics: alpha 2-antiplasmin as a model inhibitor. Biochemistry, 30, 979–986.
50. Longstaff, C. & Kolev, K. (2015) Basic mechanisms and regulation of fibrinolysis. Journal of Thrombosis and Haemostasis, 13, S98–S105.
51. Longstaff, C., Thelwell, C., Williams, S.C., Silva, M.M., Szabo, L. & Kolev, K. (2011) The interplay between tissue plasminogen activator domains and fibrin structures in the regulation of fibrinolysis: kinetic and microscopic studies. Blood, 117, 661–668.
52. Longstaff, C., Hogwood, J., Gray, E., Komorowicz, E., Varju, I., Varga, Z. & Kolev, K. (2016) Neutralisation of the anti-coagulant effects of heparin by histones in blood plasma and purified systems. Thrombosis and Haemostasis, 115, 591–599.
53. Lovejoy, A.E., Reynolds, T.C., Visich, J.E., Butine, M.D., Young, G., Belvedere, M.A., Blain, R.C., Pederson, S.M., Ishak, L.M. & Nugent, D.J. (2006) Safety and pharmacokinetics of recombinant factor XIII-A2 administration in patients with congenital factor XIII deficiency. Blood, 108, 57–62.
54. Luddington, R.J. (2005) Thrombelastography/thromboelastometry. Clinical and Laboratory Haematology, 27, 81–90.
55. Machovich, R. & Owen, W.G. (1990) The elastase-mediated pathway of fibrinolysis. Blood Coagulation & Fibrinolysis, 1, 79–90.
56. MacLeod, T.J., Kwon, M., Filipenko, N.R. & Waisman, D.M. (2003) Phospholipid-associated annexin A2-S100A10 heterotetramer and its subunits: characterization of the interaction with tissue plasminogen activator, plasminogen, and plasmin. Journal of Biological Chemistry, 278, 25577–25584.
57. Maino, A., Garagiola, I., Artoni, A., Al-Humood, S. & Peyvandi, F. (2008) A novel mutation of alpha2-plasmin inhibitor gene causes an inherited deficiency and a bleeding tendency. Haemophilia, 14, 166.
58. Mann, K.G. & Freeman, K. (2015) TACTIC: Trans-Agency Consortium for Trauma-Induced Coagulopathy. Journal of Thrombosis and Haemostasis, 13, S63–S71.
59. Manson, J., Thiemermann, C. & Brohi, K. (2012) Trauma alarmins as activators of damage-induced inflammation. British Journal of Surgery, 99, 12–20.
60. Marder, V.J. & Stewart, D. (2002) Towards safer thrombolytic therapy. Seminars in Hematology, 39, 206–216.
61. McCormack, P.L. (2012) Tranexamic acid: a review of its use in the treatment of hyperfibrinolysis. Drugs, 72, 585–617.
62. McMullan, V. & Alston, R.P. (2013) III. Aprotinin and cardiac surgery: a sorry tale of evidence misused. British Journal of Anaesthesia, 110, 675–678.
63. Medicines and Healthcare products Regulatory Agency. (2015) Alteplase for treatment of acute ischaemic stroke: independent review. The review of alteplase in the treatment of acute ischaemic stroke by the expert working group of the Commssion on Human Medicines. https://www.gov.uk/government/publications/alteplase-for-treatment-of-acute-ischaemic-stroke-independent-review
64. Mehta, R. & Shapiro, A.D. (2008) Plasminogen activator inhibitor type 1 deficiency. Haemophilia, 14, 1255–1260.
65. Meijers, J.C., Oudijk, E.J., Mosnier, L.O., Bos, R., Bouma, B.N., Nieuwenhuis, H.K. & Fijnheer, R. (2000) Reduced activity of TAFI (thrombin-activatable fibrinolysis inhibitor) in acute promyelocytic leukaemia. British Journal of Haematology, 108, 518–523.
66. Miura, O. & Aoki, N. (1990) Impaired secretion of mutant alpha 2-plasmin inhibitor (alpha 2 PI-Nara) from COS-7 and HepG2 cells: molecular and cellular basis for hereditary deficiency of alpha 2-plasmin inhibitor. Blood, 75, 1092–1096.
67. Mosnier, L.O., Lisman, T., van den Berg, H.M., Nieuwenhuis, H.K., Meijers, J.C. & Bouma, B.N. (2001) The defective down regulation of fibrinolysis in haemophilia A can be restored by increasing the TAFI plasma concentration. Thrombosis and Haemostasis, 86, 1035–1039.
68. Nogami, K., Shima, M., Matsumoto, T., Nishiya, K., Tanaka, I. & Yoshioka, A. (2007) Mechanisms of plasmin-catalyzed inactivation of factor VIII: a crucial role for proteolytic cleavage at Arg336 responsible for plasmin-catalyzed factor VIII inactivation. Journal of Biological Chemistry, 282, 5287–5295.
69. O'Connell, P.A., Madureira, P.A., Berman, J.N., Liwski, R.S. & Waisman, D.M. (2011) Regulation of S100A10 by the PML-RAR-alpha oncoprotein. Blood, 117, 4095–4105.
70. Oudijk, E.J., Nieuwenhuis, H.K., Bos, R. & Fijnheer, R. (2000) Elastase mediated fibrinolysis in acute promyelocytic leukemia. Thrombosis and Haemostasis, 83, 906–908.
71. Pealing, L., Perel, P., Prieto-Merino, D., Roberts, I. & Collaborators, C.-T. (2012) Risk factors for vascular occlusive events and death due to bleeding in trauma patients; an analysis of the CRASH-2 cohort. PLoS ONE, 7, e50603.
72. Perouansky, M., Oppenheim, A., Sprung, C.L., Eidelman, L.A. & Pizov, R. (1999) Effect of haemofiltration on pathological fibrinolysis due to severe sepsis: a case report. Resuscitation, 40, 53–56.
73. Raza, I., Davenport, R., Rourke, C., Platton, S., Manson, J., Spoors, C., Khan, S., De'Ath, H.D., Allard, S., Hart, D.P., Pasi, K.J., Hunt, B.J., Stanworth, S., MacCallum, P.K. & Brohi, K. (2013) The incidence and magnitude of fibrinolytic activation in trauma patients. Journal of Thrombosis and Haemostasis, 11, 307–314.
74. Rick, M.E. & Krizek, D.M. (1986) Platelets modulate the proteolysis of factor VIII: C protein by plasmin. Blood, 67, 1649–1654.
75. Rijken, D.C., Groeneveld, E., Kluft, C. & Nieuwenhuis, H.K. (1988) Alpha 2-antiplasmin Enschede is not an inhibitor, but a substrate, of plasmin. Biochem J, 255, 609–615.
76. Rijken, D.C., Kock, E.L., Guimarães, A.H.C., Talens, S., Murad, S.D., Janssen, H.L.A. & Leebeek, F.W.G. (2012) Evidence for an enhanced fibrinolytic capacity in cirrhosis as measured with two different global fibrinolysis tests. Journal of Thrombosis and Haemostasis, 10, 2116–2122.
77. Roberts, I. (2015) Tranexamic acid in trauma: how should we use it? Journal of Thrombosis and Haemostasis, 13, S195–S199.
78. Roberts, L.N., Patel, R.K. & Arya, R. (2010) Haemostasis and thrombosis in liver disease. British Journal of Haematology, 148, 507–521.
79. Roberts, I., Shakur, H., Afolabi, A., Brohi, K., Coats, T., Dewan, Y., Gando, S., Guyatt, G., Hunt, B.J., Morales, C., Perel, P., Prieto-Merino, D. & Woolley, T. (2011) The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial. Lancet, 377, 1096–1101, 1101 e1091-1092.
80. Royston, D., Bidstrup, B.P., Taylor, K.M. & Sapsford, R.N. (1987) Effect of aprotinin on need for blood transfusion after repeat open-heart surgery. Lancet, 2, 1289–1291.
81. Saffarzadeh, M., Juenemann, C., Queisser, M.A., Lochnit, G., Barreto, G., Galuska, S.P., Lohmeyer, J. & Preissner, K.T. (2012) Neutrophil extracellular traps directly induce epithelial and endothelial cell death: a predominant role of histones. PLoS ONE, 7, e32366.
82. Sakata, Y., Loskutoff, D.J., Gladson, C.L., Hekman, C.M. & Griffin, J.H. (1986) Mechanism of protein C-dependent clot lysis: role of plasminogen activator inhibitor. Blood, 68, 1218–1223.
83. Sawamura, A., Hayakawa, M., Gando, S., Kubota, N., Sugano, M., Wada, T. & Katabami, K. (2009) Disseminated intravascular coagulation with a fibrinolytic phenotype at an early phase of trauma predicts mortality. Thrombosis Research, 124, 608–613.
84. Schroder, L., Potzsch, B., Ruhl, H., Gembruch, U. & Merz, W.M. (2015) Tranexamic acid for hyperfibrinolytic hemorrhage during conservative management of Placenta Percreta. Obstetrics and Gynecology, 126, 1012–1015.
85. Shakur, H., Roberts, I., Bautista, R., Caballero, J., Coats, T., Dewan, Y., El-Sayed, H., Gogichaishvili, T., Gupta, S., Herrera, J., Hunt, B., Iribhogbe, P., Izurieta, M., Khamis, H., Komolafe, E., Marrero, M.A., Mejia-Mantilla, J., Miranda, J., Morales, C., Olaomi, O., Olldashi, F., Perel, P., Peto, R., Ramana, P.V., Ravi, R.R. & Yutthakasemsunt, S. (2010) Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet, 376, 23–32.
86. Shakur, H., Roberts, I., Piot, P., Horton, R., Krug, E. & Mersch, J. (2012) A promise to save 100,000 trauma patients. Lancet, 380, 2062–2063.
87. Silva, M.M., Thelwell, C., Williams, S.C. & Longstaff, C. (2012) Regulation of fibrinolysis by C-terminal lysines operates through plasminogen and plasmin but not tissue plasminogen activator (tPA). Journal of Thrombosis and Haemostasis, 10, 2354–2360.
88. Sinniger, V., Merton, R.E., Fabregas, P., Felez, J. & Longstaff, C. (1999) Regulation of tissue plasminogen activator activity by cells. Domains responsible for binding and mechanism of stimulation. Journal of Biological Chemistry, 274, 12414–12422.
89. Smith, S.A. & Morrissey, J.H. (2008) Polyphosphate enhances fibrin clot structure. Blood, 112, 2810–2816.
90. Smith, A.A., Jacobson, L.J., Miller, B.I., Hathaway, W.E. & Manco-Johnson, M.J. (2003) A new euglobulin clot lysis assay for global fibrinolysis. Thrombosis Research, 112, 329–337.
91. Souri, M., Osaki, T. & Ichinose, A. (2015) Anti-factor XIII A subunit (FXIII-A) autoantibodies block FXIII-A2 B2 assembly and steal FXIII-A from native FXIII-A2 B2. Journal of Thrombosis and Haemostasis, 13, 802–814.
92. Spahn, D.R., Bouillon, B., Cerny, V., Coats, T.J., Duranteau, J., Fernandez-Mondejar, E., Filipescu, D., Hunt, B.J., Komadina, R., Nardi, G., Neugebauer, E., Ozier, Y., Riddez, L., Schultz, A., Vincent, J.L. & Rossaint, R. (2013) Management of bleeding and coagulopathy following major trauma: an updated European guideline. Critical Care, 17, R76.
93. Taylor, F.B. Jr, Toh, C.H., Hoots, W.K., Wada, H. & Levi, M.; Scientific Subcommittee on Disseminated Intravascular Coagulation of the International Society on, Thrombosis and Haemostasis. (2001) Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thrombosis and Haemostasis, 86, 1327–1330.
94. Thelwell, C. & Longstaff, C. (2007) The regulation by fibrinogen and fibrin of tissue plasminogen activator kinetics and inhibition by plasminogen activator inhibitor 1. Journal of Thrombosis and Haemostasis, 5, 804–811.
95. Tutwiler, V., Litvinov, R.I., Lozhkin, A.P., Peshkova, A.D., Lebedeva, T., Ataullakhanov, F.I., Spiller, K.L., Cines, D.B. & Weisel, J.W. (2016) Kinetics and mechanics of clot contraction are governed by the molecular and cellular composition of the blood. Blood, 127, 149–159.
96. Varju, I., Tenekedjiev, K., Keresztes, Z., Pap, A.E., Szabo, L., Thelwell, C., Longstaff, C., Machovich, R. & Kolev, K. (2014) Fractal kinetic behavior of plasmin on the surface of fibrin meshwork. Biochemistry, 53, 6348–6356.
97. Verstraete, M. (2000) Third-generation thrombolytic drugs. American Journal of Medicine, 109, 52–58.
98. Wassenaar, T., Black, J., Kahl, B., Schwartz, B., Longo, W., Mosher, D. & Williams, E. (2008) Acute promyelocytic leukaemia and acquired alpha-2-plasmin inhibitor deficiency: a retrospective look at the use of epsilon-aminocaproic acid (Amicar) in 30 patients. Hematological Oncology, 26, 241–246.
99. Wolberg, A.S., Allen, G.A., Monroe, D.M., Hedner, U., Roberts, H.R. & Hoffman, M. (2005) High dose factor VIIa improves clot structure and stability in a model of haemophilia B. British Journal of Haematology, 131, 645–655.
100. Xue, Y., Bodin, C. & Olsson, K. (2012) Crystal structure of the native plasminogen reveals an activation-resistant compact conformation. Journal of Thrombosis and Haemostasis, 10, 1385–1396.
101. Zucker, M., Seligsohn, U., Salomon, O. & Wolberg, A.S. (2014) Abnormal plasma clot structure and stability distinguish bleeding risk in patients with severe factor XI deficiency. Journal of Thrombosis and Haemostasis, 12, 1121–1130.